Combined Application of Patient-Derived Cells and Biomaterials as 3D In Vitro Tumor Models

Although advances have been made in cancer therapy, cancer remains the second leading cause of death in the U.S. and Europe, and thus efforts to continue to study and discover better treatment methods are ongoing. Three-dimensional (3D) tumor models have shown advantages over bi-dimensional (2D) cultures in evaluating the efficacy of chemotherapy. This commentary aims to highlight the potential of combined application of biomaterials with patient-derived cancer cells as a 3D in vitro model for the study and treatment of cancer patients. Five studies were discussed which demonstrate and provided early evidence to create 3D models with accurate microenvironments that are comparable to in vivo tumors. To date, the use of patient-derived cells for a more personalized approach to healthcare in combination with biomaterials to create a 3D tumor is still relatively new and uncommon for application in clinics. Although highly promising, it is important to acknowledge the current limitations and challenges of developing these innovative in vitro models, including the need for biologists and laboratory technicians to become familiar with biomaterial scaffolds, and the effort for bioengineers to create easy-to-handle scaffolds for routine assessment.

Automated summary

This commentary highlights the potential of using biomaterials combined with patient-derived cancer cells as a 3D in vitro model for cancer research and treatment. While this approach is relatively new and uncommon in clinics, studies have shown promising results in creating 3D models that mimic in vivo tumors. However, there are limitations and challenges, including the need for familiarity with biomaterial scaffolds and the development of easy-to-handle scaffolds for routine assessment.